Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
Public ClinicalTrials.gov record NCT02494700. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma
Study identification
- NCT ID
- NCT02494700
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 50 participants
Conditions and interventions
Conditions
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- Ann Arbor Stage I Grade 2 Follicular Lymphoma
- Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma
- Ann Arbor Stage I Mantle Cell Lymphoma
- Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage II Grade 1 Follicular Lymphoma
- Ann Arbor Stage II Grade 2 Follicular Lymphoma
- Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma
- Ann Arbor Stage II Mantle Cell Lymphoma
- Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage III Grade 1 Follicular Lymphoma
- Ann Arbor Stage III Grade 2 Follicular Lymphoma
- Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma
- Ann Arbor Stage III Mantle Cell Lymphoma
- Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Grade 1 Follicular Lymphoma
- Ann Arbor Stage IV Grade 2 Follicular Lymphoma
- Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma
- Ann Arbor Stage IV Mantle Cell Lymphoma
- Ocular Adnexal Lymphoma
- Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
- Orbit Lymphoma
Interventions
- External Beam Radiation Therapy Radiation
- Orbital Radiation Drug
Radiation · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 5, 2015
- Primary completion
- Jun 29, 2027
- Completion
- Jun 29, 2027
- Last update posted
- Jan 6, 2026
2015 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02494700, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced May 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02494700 live on ClinicalTrials.gov.